Curium Completes Acquisition of Monrol to Expand Nuclear Medicine Capabilities

• Curium has finalised its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), strengthening its position in nuclear medicine.

• The acquisition increases Curium’s Lutetium-177 (Lu-177) manufacturing capacity and expands its PET & SPECT footprint across Eastern Europe and MENA.

Curium, a global leader in nuclear medicine, has completed its acquisition of Eczacıbaşı-Monrol Nuclear Products Co. (Monrol), a nuclear medicine manufacturer based in Istanbul, Turkey. The deal enhances Curium’s capabilities in Lutetium-177 (Lu-177) production to support its pipeline of radiopharmaceutical drug candidates for prostate cancer and neuroendocrine tumours.

By integrating Monrol, Curium gains access to advanced manufacturing, R&D capabilities, and an expanded theranostic product portfolio. The acquisition also strengthens Curium’s production and distribution infrastructure, adding 12 Monrol-owned and partnered PET & SPECT sites in Eastern Europe and the MENA region to Curium’s existing 34 sites in Western Europe and Asia.

In a statement, Chaitanya Tatineni, Curium’s CEO International Markets, said: “We are delighted to welcome close to 400 highly-skilled and dedicated new colleagues to Curium Group. The coming together of Curium and Monrol will transform our scale, capabilities and reach across several critical areas, in particular Lu-177, and create multiple new opportunities to enhance our offering of life-changing diagnostic and therapeutic solutions to patients around the world.”

Mr. Aydin Kucuk, General Manager of Monrol, expressed enthusiasm about joining Curium, highlighting the company’s strong capabilities, leadership, and dedication to advancing nuclear diagnostics and therapies. He emphasised Monrol’s eagerness to collaborate with their new Curium colleagues, leveraging their combined expertise, experience, and knowledge to enhance Curium’s global presence, product range, and history of innovation.

Mr. Emin Fadıllıoğlu, CEO of Eczacıbaşı Pharmaceutical and Industrial Investment, conveyed pride in Monrol’s journey and transformation over the years, which has now led to its integration with Curium, a global leader in nuclear medicine. He remarked that this milestone reflects the strength of Monrol’s business and expressed confidence that under Curium’s ownership, the company will continue to thrive, benefiting from access to advanced technology and an extensive international network.